What is claimed is:

1. A method of treating migraine, epilepsy, or bipolar disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I)



(I),

or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl;

R_A, R_B, and R_C are independently hydrogen or alkyl;

R_1 is OR_2 or NR_3R_4;

R_2 is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;

R_3 and R_4 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or



; or

R_3 and R_4 taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidinyl, aziridinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl;

R_5 and R_6 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R_7 is alkoxy, alkyl, hydroxy, or $-NR_5R_6$;

R_8 is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or $-(CH_2)_nNHC(=NH)NH_2$; and

n is an integer from 1 to 6.

2. The method according to claim 1 wherein

A is cycloalkyl; and

R_1 is OR_2.

3. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R_1 is OR_2; and

R_2 is hydrogen.

4. The method according to claim 3 wherein the compound of formula (I) is

spiro[2.5]octane-1-carboxylic acid;

(1S)-spiro[2.5]octane-1-carboxylic acid;

(1R)-spiro[2.5]octane-1-carboxylic acid;

2-methylspiro[2.5]octane-1-carboxylic acid;

5,7-dimethylspiro[2.5]octane-1-carboxylic acid;

6-tert-butylspiro[2.5]octane-1-carboxylic acid;

(4S,7R)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxylic acid; or

5,5,7,7-tetramethylspiro[2.5]octane-1-carboxylic acid.

5. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1, or 2 alkyl groups;

R_1 is OR_2; and

R_2 is hydrogen.

6. The method according to claim 5 wherein the compound of formula (I) is

spiro[2.4]heptane-1-carboxylic acid;

(1R,5S)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

2-methylspiro[2.4]heptane-1-carboxylic acid;

3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

spiro[2.6]nonane-1-carboxylic acid; or
spiro[2.7]decane-1-carboxylic acid.

7. The method according to claim 1 wherein
A is bicycloalkyl; and
R_1 is OR_2.

8. The method according to claim 1 wherein
A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl wherein the bicycloalkyl is optionally substituted with 1, or 2 alkyl groups;
R_1 is OR_2; and
R_2 is hydrogen.

9. The method according to claim 8 wherein the compound of formula (I) is
4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxylic acid;
octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxylic acid; or
spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxylic acid.

10. The method according to claim 1 wherein
A is cycloalkyl; and
R_1 is NR_3R_4.

11. The method according to claim 1 wherein
A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;
R_1 is NR_3R_4;
R_4 is hydrogen or (NR_5R_6)carbonylalkyl; and
R_3, R_5, and R_6 are hydrogen.

12. The method according to claim 11 wherein the compound of formula (I) is
spiro[2.5]octane-1-carboxamide;
N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide;
(1S)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;

(1R)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;

(1S)-spiro[2.5]octane-1-carboxamide;

(1R)-spiro[2.5]octane-1-carboxamide;

2-methylspiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-2-methylspiro[2.5]octane-1-carboxamide;

5,7-dimethylspiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-5,7-dimethylspiro[2.5]octane-1-carboxamide;

6-tert-butylspiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-6-tert-butylspiro[2.5]octane-1-carboxamide;

(4S,7R)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;

(4S,7R)-N-(2-amino-2-oxoethyl)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;

N-(3-amino-3-oxopropyl)spiro[2.5]octane-1-carboxamide;

5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide; or

N-(2-amino-2-oxoethyl)-5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide.

13. The method according to claim 11 wherein the compound of formula (I) is (1S)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

14. The method according to claim 11 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

15. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R_1 is NR_3R_4;

R_4 is carboxyalkyl or hydroxyalkyl; and

R_3 is hydrogen.

16. The method according to claim 15 wherein the compound of formula (I) is

[(spiro[2.5]oct-1-ylcarbonyl)amino]acetic acid;

{[(1S)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

{[(1R)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

(1R)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;

(1R)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;

(1S)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide; or

(1S)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide.

17. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_1 is NR_3R_4;

R_4 is hydrogen or (NR_5R_6)carbonylalkyl; and

R_3, R_5, and R_6 are hydrogen.

18. The method according to claim 17 wherein the compound of formula (I) is

spiro[2.4]heptane-1-carboxamide;

N-(2-amino-2-oxoethyl)spiro[2.4]heptane-1-carboxamide;

(1R,5S)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

2-methylspiro[2.4]heptane-1-carboxamide;

N-(2-amino-2-oxoethyl)-2-methylspiro[2.4]heptane-1-carboxamide;

3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)-3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

spiro[2.6]nonane-1-carboxamide;

N-(2-amino-2-oxoethyl)spiro[2.6]nonane-1-carboxamide;

spiro[2.7]decane-1-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[2.7]decane-1-carboxamide.

19. The method according to claim 1 wherein

A is bicycloalkyl; and

R_1 is NR_3R_4.

20. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_1 is NR_3R_4;

R_4 is hydrogen or (NR_5R_6)carbonylalkyl; and

R_3, R_5, and R_6 are hydrogen.

21. The method according to claim 20 wherein the compound of formula (I) is

4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)-4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide;

spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide.

22. A method of treating pain, a movement disorder, or a psychiatric disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

23. The method according to claim 22 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

24. A method of providing neuroprotection in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

25. The method according to claim 24 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

26. A compound of formula (II)



(II),

or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl wherein the cycloalkyl and bicycloalkyl are optionally substituted with 1, 2, 3, or 4 alkyl groups;

R_A, R_B, and R_C are independently hydrogen or alkyl;

R_3 is alkenyl, alkynyl, alkoxycarbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR_5R_6)alkyl, or (NR_5R_6)carbonylalkyl;

R_4 is hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR_5R_6)alkyl, or (NR_5R_6)carbonylalkyl, or


; or

R_3 and R_4 taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidinyl, aziridinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl;

R_5 and R_6 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;

R_7 is alkoxy, alkyl, hydroxy, or $-NR_5R_6$;

R_8 is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or $-(CH_2)_nNHC(=NH)NH_2$; and

n is an integer from 1 to 6.

27. The compound according to claim 26 wherein A is cycloalkyl optionally substituted with 1, 2, 3, or 4 alkyl groups.

28. The compound according to claim 26 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R_3 is (NR_5R_6)carbonylalkyl; and

R_4, R_5, and R_6 are hydrogen.

29. The compound according to claim 28 wherein the compound of formula (II) is

N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide;

(1S)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;

(1R)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-2-methylspiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-5,7-dimethylspiro[2.5]octane-1-carboxamide;

N-(2-amino-2-oxoethyl)-6-tert-butylspiro[2.5]octane-1-carboxamide;

(4S,7R)-N-(2-amino-2-oxoethyl)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;

N-(3-amino-3-oxopropyl)spiro[2.5]octane-1-carboxamide; or

N-(2-amino-2-oxoethyl)-5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide.

30. The compound according to claim 28 wherein the compound of formula (II) is (1S)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

31. The compound according to claim 28 wherein the compound of formula (II) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

32. The compound according to claim 26 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R_3 is carboxyalkyl or hydroxyalkyl; and

R_4 is hydrogen.

33. The compound according to claim 32 wherein the compound of formula (II) is

[(spiro[2.5]oct-1-ylcarbonyl)amino]acetic acid;

{[(1S)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

{[(1R)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

(1R)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;

(1S)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;

(1R)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide; or

(1S)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide.

34. The compound according to claim 26 wherein

A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_3 is (NR_5R_6)carbonylalkyl; and

R_4, R_5, and R_6 are hydrogen.

35. The compound according to claim 34 wherein the compound of formula (II) is

N-(2-amino-2-oxoethyl)spiro[2.4]heptane-1-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)-2-methylspiro[2.4]heptane-1-carboxamide;

N-(2-amino-2-oxoethyl)-3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)spiro[2.6]nonane-1-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[2.7]decane-1-carboxamide.

36. The compound according to claim 26 wherein A is bicycloalkyl optionally substituted with 1, 2, 3, or 4 alkyl groups.

37. The compound according to claim 26 wherein

A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl, wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_3 is (NR_5R_6)carbonylalkyl; and

R_4, R_5, and R_6 are hydrogen.

38. The compound according to claim 37 wherein the compound of formula (II) is

N-(2-amino-2-oxoethyl)-4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide.

39. A method of treating neuropathic and inflammatory pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).